QuidelOrtho (QDEL) Q2 2026 earnings review
A Disastrous Guidance Cut Shadows a Decent Quarter
QuidelOrtho managed a 3% revenue beat in Q2, driven by 6% growth outside of China and a 16% surge in Point of Care. However, the market will ignore the rear-view mirror because the forward outlook has collapsed. Management slashed full-year Adjusted EPS guidance by nearly 60%, citing a softer global respiratory environment and severe distributor pushback in China over pending IVD pricing guidelines. Most alarmingly, the company completely withdrew its free cash flow guidance due to working capital issues—a glaring red flag that signals deep operational turbulence despite recent cost-cutting successes.
🐂 Bull Case
Excluding China, total revenue grew 6%. The core Labs business ex-China was a standout, accelerating 9% YoY, proving the underlying clinical chemistry and immunoassay installed base remains sticky.
Despite top-line pressure, Adjusted EBITDA margin in Q2 improved 310 basis points YoY to 20.5%. Previous headcount reductions and procurement savings are successfully flowing through to the operating line.
🐻 Bear Case
Withdrawing Free Cash Flow guidance midway through the year is highly concerning. First-half operating cash flow sits at a negative $143.6M, suggesting severe working capital bottlenecks.
China revenue fell 19%, with Immunohematology down a staggering 38%. Distributors are freezing orders ahead of sweeping IVD pricing guidelines, and there is no clear timeline for stabilization.
⚖️ Verdict: 🔴🔴
Strongly Bearish. A massive 60% cut to EPS guidance and a withdrawn cash flow metric entirely overshadow any localized strength in the Point of Care or ex-China Labs segments. The company is flying blind on working capital.
Key Themes
The Free Cash Flow Red Flag
The most alarming data point in the release is the complete withdrawal of the $100-$120M Free Cash Flow guidance. Management cited 'associated impacts on working capital and our mitigation efforts.' Year-to-date operating cash flow is already reversing violently, landing at negative $143.6M compared to positive $18.8M last year. When a management team pulls a cash flow guide mid-year, it signals acute internal visibility issues regarding collections or inventory.
China IVD Pricing Shock
The long-feared impact of China's Value-Based Procurement (VBP) and IVD pricing guidelines has arrived with brutal force. China revenue decelerated 19% overall, with China Labs down 19.6% and China Immunohematology collapsing 38.0%. Management explicitly blamed these declines on the new pricing guidelines, contradicting earlier narratives from 2025 that their business was 'insulated' and 'differentiated' from VBP.
Respiratory Demand Evaporating (Macro)
A 'softer global respiratory environment' was cited as a primary reason for the slashed full-year outlook. While the company has been trying to pivot the narrative away from COVID and flu dependency, the sheer magnitude of the guidance cut reveals that respiratory volume still acts as a critical anchor for operating leverage.
Point of Care (POC) Accelerating
A bright spot in the quarter: POC revenue surged 16% to $108 million, driven by 10% growth in the Triage product line. This highlights successful execution in non-respiratory, decentralized testing environments, providing a crucial growth engine while the respiratory segment normalizes.
Ex-China Labs Showing Durability
When stripping out the noise from China, the core recurring revenue engine remains healthy. Labs revenue excluding China grew 9% YoY. This indicates that competitive tender wins, VITROS analyzer placements, and assay pull-through remain strong in North America and EMEA.
Margin Promises vs. Reality Contradiction
In Q2, cost-cutting initiatives worked beautifully, driving Adjusted EBITDA margin up 310 bps YoY to 20.5%. However, this backward-looking success contradicts the forward-looking panic: management downgraded full-year Adjusted EBITDA margin guidance from 23% to 21-22%. The lost volume leverage from China and respiratory is overwhelming their previously lauded $140M+ cost-savings program.
Other KPIs
Stable but ugly. The company reported a GAAP net loss of $92.9 million for the quarter. While Adjusted EBITDA looks healthy, the massive gap between GAAP and Non-GAAP highlights heavy ongoing amortization ($49M) and interest expenses ($54.7M) that continue to drain actual profitability.
Accelerating significantly from $80.5 million in the first half of 2025. With a high debt load and leverage ratio, the rising cost of debt service makes the company's negative operating cash flow and withdrawn free cash flow guidance even more precarious.
Guidance
Decelerating. Slashed from the previous expectation of $2.70 - $2.75 billion. This implies a significant contraction in the second half of the year, driven almost entirely by the sudden freeze in China purchasing and expected respiratory weakness.
Reversing. Down from the $615 - $630 million range provided just a quarter ago. The margin target was also lowered to 21-22% from 23%, abandoning the narrative that the company was steadily marching toward a 25%+ long-term margin profile.
Reversing violently. The previous guidance was $1.80 - $2.00. The midpoint of $0.78 represents a stunning 59% cut to earnings expectations, reflecting the severe lack of operating leverage as high-margin China and respiratory revenues evaporate.
Reversing. The prior expectation was $100 - $120 million. Pulling this metric implies management lacks visibility into inventory adjustments, accounts receivable collections, or the timing of supplier payments amidst the China disruption.
Key Questions
Working Capital Black Hole
You withdrew free cash flow guidance entirely, citing 'impacts on working capital.' Exactly which line item—inventory ballooning, uncollectible AR in China, or accelerated AP—broke the model, and when do you expect cash conversion to normalize?
China Stabilization Timeline
With China Labs and IH down 20% and 38% respectively, how much of this is distributors merely pausing to burn off inventory ahead of new pricing, versus permanent structural demand destruction?
LEX Diagnostics Funding
Given the negative $143M in first-half operating cash flow and a high debt load, does the current cash crunch jeopardize the commercial launch timeline or manufacturing scale-up for the newly acquired LEX Diagnostics platform?